Dec 03, 2024 8:25am EST DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia
Nov 13, 2024 4:20pm EST DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results
Nov 13, 2024 4:05pm EST DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia
Nov 12, 2024 8:23am EST DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference
Nov 06, 2024 8:32am EST DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024
Oct 09, 2024 8:27am EDT DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia
Aug 07, 2024 4:15pm EDT DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results
Aug 01, 2024 8:20am EDT DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024
Jul 11, 2024 8:00am EDT DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
